ACHN might be able to ink some “regional” deals for elvucitabine, but I doubt that they will be lucrative ones.
I don't expect anything lucrative either. Kishbauch kind of grouped the partnering discussion of elvucitabine and ACH-702 together as these compounds fall outside of ACHN's primary HCV focus. He acknowledged that ACHN expects the licensing deal for ACH-702 to be more lucrative than the one for elvucitabine.
Market Data 
Markets 
AI
